FBR Capital Markets Begins Coverage on Alcobra (ADHD)
Equities research analysts at FBR Capital Markets assumed coverage on shares of Alcobra (NASDAQ:ADHD) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “market perform” rating and a $23.00 price target on the stock. FBR Capital Markets’ price target indicates a potential upside of 11.60% from the stock’s previous close.
ADHD has been the subject of a number of other recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Alcobra in a research note on Monday, August 4th. They set an “overweight” rating and a $42.00 price target on the stock. Separately, analysts at Roth Capital initiated coverage on shares of Alcobra in a research note on Friday, August 1st. They set a “buy” rating and a $40.00 price target on the stock. Finally, analysts at WBB Securities initiated coverage on shares of Alcobra in a research note on Thursday, June 26th. They set a “hold” rating and a $18.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $32.29.
Shares of Alcobra (NASDAQ:ADHD) traded down 2.34% on Wednesday, hitting $20.1271. The stock had a trading volume of 58,461 shares. Alcobra has a 52 week low of $12.04 and a 52 week high of $26.96. The stock’s 50-day moving average is $19.07 and its 200-day moving average is $18.87. The company’s market cap is $275.0 million.
Alcobra (NASDAQ:ADHD) last announced its earnings results on Monday, August 11th. The company reported ($0.57) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.57). Analysts expect that Alcobra will post $-2.16 EPS for the current fiscal year.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.